JPWO2023018809A5 - - Google Patents
Info
- Publication number
- JPWO2023018809A5 JPWO2023018809A5 JP2024507885A JP2024507885A JPWO2023018809A5 JP WO2023018809 A5 JPWO2023018809 A5 JP WO2023018809A5 JP 2024507885 A JP2024507885 A JP 2024507885A JP 2024507885 A JP2024507885 A JP 2024507885A JP WO2023018809 A5 JPWO2023018809 A5 JP WO2023018809A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- fluoro
- methoxy
- pyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231543P | 2021-08-10 | 2021-08-10 | |
| US63/231,543 | 2021-08-10 | ||
| US202163289576P | 2021-12-14 | 2021-12-14 | |
| US63/289,576 | 2021-12-14 | ||
| PCT/US2022/039968 WO2023018809A1 (en) | 2021-08-10 | 2022-08-10 | Heterocyclic compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532735A JP2024532735A (ja) | 2024-09-10 |
| JPWO2023018809A5 true JPWO2023018809A5 (enrdf_load_html_response) | 2025-08-19 |
Family
ID=85201031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024507885A Pending JP2024532735A (ja) | 2021-08-10 | 2022-08-10 | 複素環式化合物及び使用方法 |
Country Status (8)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118139855A (zh) * | 2021-08-18 | 2024-06-04 | 北京加科思新药研发有限公司 | 1,4-氧杂氮杂环庚烷衍生物及其用途 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| CN119585287A (zh) | 2022-05-06 | 2025-03-07 | Paq医疗公司 | Kras g12d蛋白水解靶向嵌合体 |
| WO2023213269A1 (en) * | 2022-05-06 | 2023-11-09 | Zai Lab (Shanghai) Co., Ltd. | Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof |
| JP7735594B2 (ja) | 2022-05-19 | 2025-09-08 | ジェネンテック， インコーポレイテッド | アザ四環式オキサゼピン化合物及びその使用 |
| KR20250022133A (ko) | 2022-06-10 | 2025-02-14 | 레볼루션 메디슨즈, 인크. | 거대고리 ras 억제제 |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| CN116969977A (zh) * | 2022-07-13 | 2023-10-31 | 北京华森英诺生物科技有限公司 | Pan-kras抑制剂 |
| KR20250109197A (ko) | 2022-11-21 | 2025-07-16 | 트리라인 바이오사이언시스, 인크. | 스피로환식 디하이드로피라노피리미딘 KRas 억제제 |
| WO2024119277A1 (en) * | 2022-12-08 | 2024-06-13 | Risen (Suzhou) Pharma Tech Co., Ltd. | Kras inhibitors and pharmaceutical uses thereof |
| TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| WO2024216048A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025016899A1 (en) | 2023-07-19 | 2025-01-23 | Bayer Aktiengesellschaft | Spirocyclic compounds for the treatment of cancer |
| WO2025026903A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | Imidazo pyrimidine compounds for the treatment of cancer |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025038936A1 (en) | 2023-08-17 | 2025-02-20 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025064542A1 (en) * | 2023-09-20 | 2025-03-27 | Alterome Therapeutics, Inc. | Kras modulators |
| WO2025064848A1 (en) | 2023-09-21 | 2025-03-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyridine kras inhibitors |
| US20250144225A1 (en) | 2023-10-03 | 2025-05-08 | PAQ Therapeutics Inc. | KRAS Proteolysis Targeting Chimeras |
| WO2025076288A1 (en) | 2023-10-06 | 2025-04-10 | Amgen Inc. | Combination therapy for cancer treatment |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103588792B (zh) * | 2013-03-04 | 2016-03-23 | 中国科学院上海药物研究所 | 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 |
| JP7592601B2 (ja) * | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| PH12022550469A1 (en) * | 2019-08-29 | 2023-02-27 | Array Biopharma Inc | Kras g12d inhibitors |
| CA3198885A1 (en) * | 2020-12-15 | 2022-06-23 | Xiaolun Wang | Azaquinazoline pan-kras inhibitors |
-
2022
- 2022-08-10 AU AU2022328206A patent/AU2022328206A1/en active Pending
- 2022-08-10 CA CA3228579A patent/CA3228579A1/en active Pending
- 2022-08-10 JP JP2024507885A patent/JP2024532735A/ja active Pending
- 2022-08-10 EP EP22856566.9A patent/EP4384159A4/en active Pending
- 2022-08-10 US US18/695,673 patent/US20250122222A1/en active Pending
- 2022-08-10 TW TW111130116A patent/TW202321242A/zh unknown
- 2022-08-10 WO PCT/US2022/039968 patent/WO2023018809A1/en not_active Ceased
- 2022-08-10 MX MX2024001894A patent/MX2024001894A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023018809A5 (enrdf_load_html_response) | ||
| JP7380507B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| KR102304108B1 (ko) | 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 | |
| JP2018531983A (ja) | タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法 | |
| RU2508110C2 (ru) | КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek | |
| JPWO2023018810A5 (enrdf_load_html_response) | ||
| CN107864625B (zh) | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 | |
| JP6695353B2 (ja) | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 | |
| KR20160132130A (ko) | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 | |
| TW200538128A (en) | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | |
| JP2019501195A5 (ja) | 腫瘍を処置するための抗ｅｇｆｒ組み合わせ | |
| JPWO2022232331A5 (enrdf_load_html_response) | ||
| JP2017528487A5 (enrdf_load_html_response) | ||
| ES2896079T3 (es) | Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario | |
| TW201032806A (en) | Hsp90 inhibitor combinations | |
| JP2019501196A5 (ja) | 腫瘍を処置するための抗ｃｄ２０組み合わせ | |
| WO2022187527A1 (en) | Quinazoline nitrile derivatives as kras inhibitors | |
| KR20180013850A (ko) | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 | |
| TW201245202A (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| WO2024091409A1 (en) | Tricyclic derivatives as kras inhibitors | |
| JP2023522045A (ja) | アリール炭化水素受容体モジュレーターとしてのピリドピリミジノン誘導体およびその使用 | |
| KR20250081951A (ko) | 금속 채널 활성화제를 포함하는 병용 요법 | |
| TW202131917A (zh) | 併用醫藥 | |
| FI3773595T3 (fi) | Syöpälääkekoostumuksia yhdistelmähoitoon | |
| AU2009319050B2 (en) | Pharmaceutical combinations comprising a pyrido [4, 3-d] pyrimidine derived Hsp90-inhibitor and a HER2 inhibitor |